We prospectively evaluated a risk-adapted pre-emptive treatment with ganciclovir for CMV diseases in patients undergoing allogeneic bone marrow transplantation (BMT). High-level CMV antigenemia (10 or more positive cells on two slides) or CMV antigenemia at any level in patients with grade II-IV acute graft-versus-host disease (aGVHD) were chosen as risk factors. We also retrospectively evaluated virus reactivation in plasma using quantitative real-time polymerase chain reaction (PCR). Fifty patients were evaluable. None of the 27 patients with or without grade I aGVHD developed high-level CMV antigenemia or CMV disease. Among the 23 patients with grade II-IV aGVHD, 12 patients (52%) developed CMV antigenemia and were treated pre-emptively, of whom two developed CMV gastroenteritis or retinitis in spite of therapy. Six of the remaining 11 patients developed CMV gastroenteritis before CMV antigenemia was detectable. All of the eight patients with CMV diseases were successfully treated with ganciclovir and no deaths directly related to CMV disease occurred. In four of the seven evaluable patients with CMV gastroenteritis, real-time PCR was able to detect virus reactivation earlier than CMV antigenemia. Although our risk-adapted pre-emptive therapy effectively reduced CMV-related mortality, further refinements of this approach, particularly in the prevention of CMV gastroenteritis, may be achieved by incorporating real-time PCR. Bone Marrow Transplantation (2000) 25, 765-769.
high. 2 Thus, recent therapeutic strategies have focused on the prevention of CMV diseases.
Some studies have demonstrated a reduction in the incidence of CMV diseases with the prophylactic use of ganciclovir. However, a major drawback of this approach is that it allows the occurrence of neutropenia, which has been associated with secondary bacterial/fungal infections. 3, 4 An alternative approach is to commence therapy with ganciclovir at the time CMV reactivation is detected but before the onset of CMV diseases (pre-emptive therapy). 5, 6 Recently, detection of CMV pp65 antigen (CMV antigenemia) in peripheral blood leukocytes has been widely used as a rapid and sensitive method for identifying CMV reactivation. CMV antigenemia-guided pre-emptive therapy has been shown to be effective in preventing CMV disease and in reducing the toxicity of ganciclovir. 7, 8 However, it remains uncertain whether ganciclovir administration is indicated for all transplant recipients with positive CMV antigenemia to prevent progression to overt CMV disease. To address this question, we prospectively gave risk-adapted preemptive ganciclovir therapy. This therapy was initiated according to the quantitative levels of CMV antigenemia and grade of acute graft-versus-host disease (aGVHD). We also assessed the efficacy of a novel quantitative real-time polymerase chain reaction (PCR) 9 for detection of CMV reactivation in high-risk patients.
Patients and methods

Patients and transplant procedures
CMV-seropositive patients or CMV-seronegative patients with seropositive donors, who underwent allogeneic bone marrow transplant (BMT) at Keio University Hospital, were eligible for this study. No patients received T celldepleted marrow. Herpes simplex virus (HSV)-seropositive patients received acyclovir at a dose of 250 mg/body intravenously every 8 h from day −3 to day 14. All patients received CMV hyperimmunoglobulin (5 g) once a week starting on day 1 until day 100. Blood products were not screened for CMV antibody, but were filtered to remove leukocytes before transfusion. Conditioning and GVHD prophylaxis were given according to the current protocols. Except for solitary gastric GVHD, which was determined as grade I aGVHD, aGVHD was graded according to the published criteria. 10 All patients with grade II-IV aGVHD were treated with steroids in addition to cyclosporin A (CsA) or tacrolimus.
Risk-adapted pre-emptive therapy
After engraftment, patients were monitored for CMV antigenemia once a week. When CMV antigenemia was detected, the test was performed twice a week. If (1) highlevel CMV antigenemia (10 or more positive cells on two slides) was detected; or (2) CMV antigenemia at any level was detected in patients with grade II-IV aGVHD, ganciclovir was started at a dose of 5 mg/kg body weight twice daily for 14 days. If antigenemia remained positive after this 14-day therapy, ganciclovir was continued at a dose of 5 mg/kg once daily or less until the antigenemia resolved. In patients with low-level CMV antigenemia (less than 10 positive cells on two slides), but without grade II-IV aGVHD, ganciclovir was not started and the patients were closely monitored for CMV antigenemia levels as described above. Granulocytopenia (absolute neutrophil count Ͻ1 × 10 9 /l for 2 consecutive days) during or after ganciclovir therapy was initially treated with filgrastim at a dose of 5 g/kg. If granulocytopenia persisted, a dose reduction or discontinuation of ganciclovir was considered. The dose was also adjusted according to serum creatinine concentration or creatinine clearance. CMV diseases were treated with ganciclovir at the same dose as that used in pre-emptive therapy.
CMV antigenemia assay
The antigenemia assay was performed according to previously reported methods. 11 Briefly, EDTA-treated whole blood samples were fractionated by dextran sedimentation and lysis of erythrocytes. The granulocytes were then centrifuged to prepare a cytospin slide (150 000 granulocytes per slide). The cells were then fixed with formaldehyde, sequentially immunostained by monoclonal antibodies C10/C11 (Clonab CMV; Biotest, Dreieich, Germany), and reacted with goat alkaline phosphatase-labeled anti-mouse immunoglobulin (Yuka Medias Co, Ibaraki, Japan). The examination was performed in duplicate.
Definition of CMV diseases
CMV pneumonia was defined as interstitial infiltrates on chest radiograph accompanied by histologic demonstration of CMV in lung biopsy material or a positive CMV culture from bronchoalveolar lavage fluid. CMV gastroenteritis was defined as gastrointestinal symptoms accompanied by histologic demonstration of CMV or a positive CMV culture from biopsy material obtained by endoscopy. CMV retinitis was diagnosed based on characteristic retinal changes. Late CMV disease was defined as disease occurring after day 100.
Real-time PCR
Plasma samples were collected, aliquoted, stored at −80°C, and immediately thawed before examination. Real-time PCR was performed basically using the previously reported methods. 9 DNA extracted from 100 l plasma using a QIAamp Blood Mini Kit (QIAGEN, Valencia, CA, USA) was subjected to PCR. Sequences of PCR primers and probe, obtained from Greiner Japan (Tokyo, Japan), were selected from the US17 region of CMV AD169. The sequences of forward and reverse primers were 5Ј-GCGTGCTTTTTAGCCTCTGCA-3Ј and 5Ј-AAAAGTTT GTGCCCCAACGGTA-3Ј, respectively. The Taqman probe selected between the primers was dual-labeled with FAM (6-carboxyfluorescein) at the 5Ј-end as a reporter dye and with TAMRA (6-carboxy-teremethyl-rhodamine) at the 3Ј-end as a quenching dye, whose sequence was 5Ј-TGATCGGCGTTATCGCGTTCTTGATC-3Ј. PCR reaction was performed by using TaqMan Universal PCR Master Mix (PE Biosystems, Foster City, CA, USA) and nuclease degradation of the probe was detected as an increase in fluorescent intensity by ABI Prism 7700 (PE Biosystems). DNA extracted from CMV AD169 (American Type Culture Collection, Rockville, MD, USA) was amplified using the above primers and inserted into pCR2.1 TAcloning vector (Invitrogen, Carlsbad, CA, USA), which was used as the CMV standard. The quantification of CMV was carried out with serially diluted standards ranging from 10 to 1 × 10 7 copies/well and calculation of the gene copy numbers by Sequence Detection System ver.1.6.3. software (PE Biosystems). The fluorescent intensity of each well was measured every 7 s, and determined positive if the intensity exceeded 10 times the standard deviation of the base line. The sensitivity was 20 copies per well.
Statistical methods
Statistical analysis was performed using the Chi-square test or Fisher's exact test where appropriate. A level of P Ͻ 0.05 was accepted as statistically significant.
Results
Study population
Fifty-four consecutive CMV-seropositive patients or seronegative patients with seropositive donors underwent allogeneic BMT at Keio University Hospital from August 1996 to November 1998. Of these patients, three early deaths and a case involving protocol violation were excluded. The characteristics of the remaining 50 evaluable patients are shown in Table 1 .
CMV antigenemia and CMV diseases
Of the 50 evaluable patients, 22 (44%) developed CMV antigenemia. The median post-transplant day of the first detection of CMV antigenemia was day 38.2 (range 26-55). Among 27 patients with no or grade I aGVHD, four (15%) developed low-level antigenemia, which became negative without initiation of therapy (Figure 1) . The remaining 23 patients did not develop CMV antigenemia. Among 23 patients with grade II-IV aGVHD, 12 (52%) patients developed CMV antigenemia and were treated pre- late CMV disease n = 1 Figure 1 Incidence of CMV antigenemia and diseases in bone marrow transplant recipients followed by risk-adapted pre-emptive therapy. Among 27 patients with grade 0-I acute GVHD, none developed CMV disease and four (15%) developed low-level CMV antigenemia. In contrast, among 23 patients with grade II-IV acute GVHD, 12 (52%) developed CMV antigenemia and received pre-emptive therapy, in whom two patients subsequently developed CMV disease. One patient developed late CMV pneumonia. Among the remaining 11 patients, six patients developed CMV gastroenteritis whose CMV antigenemia became positive after clinical manifestations.
Bone Marrow Transplantation emptively with ganciclovir. Two of the 12 patients developed CMV disease (one gastroenteritis and one retinitis) in spite of pre-emptive therapy (Figure 1 ). Of the remaining 11 patients, six developed CMV gastroenteritis before CMV antigenemia became positive ( Figure 1 ). All of the eight patients who developed CMV disease were successfully treated with ganciclovir. None of the 50 evaluable patients developed CMV pneumonia within day 100.
Incidence of late CMV diseases
Of the 50 patients studied, only one patient developed late CMV pneumonia. This patient developed CMV antigenemia on day 38, which became negative following preemptive ganciclovir therapy. In spite of the successful preemptive therapy, this patient subsequently developed CMV pneumonia around day 120 (Figure 1 ). CMV antigenemia did not precede the onset of late CMV pneumonia.
Incidence of neutropenia
Of 18 patients treated with ganciclovir either pre-emptively (12 patients) or therapeutically (six patients), three (17%) developed granulocytopenia, which was successfully treated with filgrastim. No documented bacterial or fungal infections were observed during the period of neutropenia in the patients. Dose modification of ganciclovir due to neutropenia was not required in any of the study patients.
Clinical factors predictive for the development of CMV antigenemia
The occurrence of grade II-IV aGVHD was significantly associated with the development of CMV antigenemia (P Ͻ 0.01). Other factors including type of donor, prophy-laxis of acute GVHD, and pretransplant CMV serostatus of the recipients were not significantly associated.
Efficacy of real-time PCR
Risk-adapted pre-emptive therapy based upon CMV antigenemia and aGVHD was effective only to a small degree in preventing the occurrence of CMV gastroenteritis and retinitis. CMV diseases developed before CMV antigenemia became positive in most cases. Therefore, we retrospectively evaluated the efficacy of quantitative real-time PCR in detecting CMV reactivation in the plasma of seven patients with CMV gastroenteritis (Table 2 ). Plasma samples stored on or around the same day of antigenemia monitoring were used. Real-time PCR detected CMV reactivation before CMV antigenemia developed in four of the seven patients (Table 2 ). Real-time PCR detected CMV reactivation before or at the onset of CMV gastroenteritis in six of the seven patients, whereas CMV antigenemia did so in two of the seven patients (Table 2 ). In addition, the results of real-time PCR closely correlated with the presence of gastroenteritis and the effect of antiviral therapy in four patients, whereas CMV antigenemia showed no correlation.
Discussion
In this study, we evaluated the efficacy and safety of a riskadapted pre-emptive therapy using ganciclovir to prevent CMV disease in recipients of allografts from both HLAmatched siblings and unrelated donors. Our risk-adapted therapy involves (1) initiating ganciclovir therapy upon the detection of a high-level of CMV antigenemia; or (2) initiating ganciclovir therapy upon detection of a low-level CMV antigenemia in patients with grade II-IV aGVHD, recognized as the most significant risk factor for the development of CMV disease. 1 In this study, 18 (36%) of 50 patients were treated with ganciclovir either pre-emptively Table 2 Comparison of CMV antigenemia and real-time PCR in the detection of CMV reactivation in patients who developed CMV gastroenteritis or therapeutically, such that we could avoid administering ganciclovir to the remaining 32 patients without increasing the risk of CMV-associated mortality. Our data also suggest that if CMV antigenemia does not develop or remains at a low-level, patients without grade II-IV aGVHD are not at risk of developing CMV disease and therefore could be followed without commencing ganciclovir pre-emptively. Our strategy resulted in the effective prevention of the occurrence of CMV pneumonia. No deaths due to CMV disease were observed in this study. However, as has been pointed out in a previous report, 7 CMV antigenemia did not necessarily predict the occurrence of CMV gastroenteritis. To overcome this disadvantage of CMV antigenemia, more sensitive methods should be used for particular patients who are at high risk of developing CMV disease. Some reports have shown the efficacy of standard or semiquantitative PCR of whole blood or peripheral leukocytes to detect the early stage of CMV reactivation. [12] [13] [14] [15] Therefore, we retrospectively evaluated the sensitivity and efficacy of a novel quantitative real-time PCR. Although standard PCR was of less clinical use than the antigenemia assay because of lack of quantification with PCR, this assay provides accurate and reproducible quantification of gene copies. 9 Our data suggest that real-time PCR is helpful in detecting CMV reactivation before patients developed CMV gastroenteritis, and also in evaluating the effects of antiviral therapy. Moreover, in view of possible overtreatment based on this highly sensitive assay, we consider that the PCR-oriented pre-emptive therapy should be reserved only for patients with moderate to severe aGVHD, who are at high risk of developing CMV disease.
In this study, we were not able to assess the efficacy of our novel approach to prevent CMV disease in recipients of T cell-depleted grafts. These patients are also at high risk of developing CMV disease after transplantation, and we consider that it will also be important to determine the efficacy of our risk-adapted pre-emptive therapy for CMV diseases in these patients.
One patient pre-emptively treated with ganciclovir developed late CMV pneumonia. Some reports have described the increased incidence of late CMV diseases in patients receiving ganciclovir prophylactically, as it delayed the reconstitution of CMV-specific T cell responses. 16 Although the incidence of the late diseases might be lower with pre-emptive therapy than with prophylactic therapy, the occurrence of late CMV disease in patients receiving pre-emptive therapy should be the subject of a longitudinal evaluation.
We conclude that our risk-adapted pre-emptive therapy based upon CMV antigenemia could effectively prevent the occurrence of CMV pneumonia and CMV-related mortality, without risking increased toxicity and overtreatment. Further studies of risk-adapted pre-emptive therapy should focus on exploring better approaches toward the prevention of CMV gastroenteritis in high-risk patients through the use of more sensitive PCR-oriented pre-emptive therapies.
